Title |
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma
|
---|---|
Published by |
John Wiley & Sons, Ltd, August 2011
|
DOI | 10.1002/14651858.cd007941.pub2 |
Pubmed ID | |
Authors |
Bauer, Kathrin, Skoetz, Nicole, Monsef, Ina, Engert, Andreas, Brillant, Corinne |
Abstract |
There are two different international standards for the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL): chemotherapy with escalated BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone) regimen and chemotherapy with ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) regimen. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | 2% |
Unknown | 52 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 7 | 13% |
Researcher | 6 | 11% |
Student > Ph. D. Student | 6 | 11% |
Student > Master | 5 | 9% |
Student > Bachelor | 5 | 9% |
Other | 11 | 21% |
Unknown | 13 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 42% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
Biochemistry, Genetics and Molecular Biology | 3 | 6% |
Agricultural and Biological Sciences | 2 | 4% |
Philosophy | 1 | 2% |
Other | 4 | 8% |
Unknown | 16 | 30% |